Thioredoxin in human and experimental sepsis

Critical Care Medicine

Volumn 37, Issue 7, 2009, Pages 2155-2159

  Hofer, Stefan ^a   Rosenhagen, Claudia ^a   Nakamura, Hajime ^b   Yodoi, Junji ^c   Bopp, Christian ^a   Zimmermann, Johannes B ^a   Goebel, Meike ^d   Schemmer, Peter ^a   Hoffmann, Kartrin ^a   Schulze Osthoff, Klaus ^e   Breitkreutz, Raoul ^f   Weigand, Markus A ^a,g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Kitano Hospital   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d Institute of Transfusion Medicine and Immunology   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

thioredoxin; sepsis; reactive oxygen species; migration inhibitory factor; thioredoxin reductase

Indexed keywords

RECOMBINANT PROTEIN; RECOMBINANT THIOREDOXIN; THIOREDOXIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVOR; TREATMENT OUTCOME; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE MODEL; INTENSIVE CARE; MIDDLE AGED; MORTALITY; OXIDATIVE STRESS; PHYSIOLOGY; SURVIVAL RATE;

ADULT; ANIMALS; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTENSIVE CARE; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; OXIDATIVE STRESS; PERITONITIS; RECOMBINANT PROTEINS; SEPSIS; SURVIVAL RATE; THIOREDOXINS;

EID: 67649818180     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819fff67     Document Type: Article

References (44)

1. Laurent TC, Moore EC, Reichard P: Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem 1964; 239:3436-3444
2. Arner ES, Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267:6102-6109
3. Holmgren A: Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2000; 2:811-820
4. Mitsui A, Hirakawa T, Yodoi J: Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Biochem Biophys Res Commun 1992; 186:1220-1226
5. Mustacich D, Powis G: Thioredoxin reductase. Biochem J 2000; 346(Pt 1):1-8
6. Tagaya Y, Maeda Y, Mitsui A, et al: ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 1989; 8:757-764
7. Tagaya Y, Wagasugi H, Masutani H, et al: Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: Involvement of dithiol related reduction. Mol Immunol 1990; 27:1279-1289
8. Hirota K, Matsui M, Iwata S, et al: AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad SciUSA 1997; 94: 3633-3638
9. Hirota K, Murata M, Sachi Y, et al: Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NFkappaB. J Biol Chem 1999; 274:27891-27897
10. Powis G, Montfort WR: Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001; 30:421-455
11. Abdiu A, Nakamura H, Sahaf B, et al: Thioredoxin blood level increases after severe burn injury. Antioxid Redox Signal 2000; 2:707-716
12. Callister ME, Burke-Gaffney A, Quinlan GJ, et al: Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 2006; 61:521-527
13. Jekell A, Hossain A, Alehagen U, et al: Elevated circulating levels of thioredoxin and stress in chronic heart failure. Eur J Heart Fail 2004; 6:883-890
14. Jikimoto T, Nishikubo Y, Koshiba M, et al: Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 2002; 38:765-772
15. Kato A, Odamaki M, Nakamura H, et al: Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection. Kidney Int 2003; 63:2262-2268
16. Miyazaki K, Noda N, Okada S, et al: Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 1998; 11:277-288
17. Nakamura H, De Rosa S, Roederer M, et al: Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 1996; 8:603-611
18. Okuyama H, Nakamura H, Shimahara Y, et al: Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. Hepatology 2003; 37:1015-1025
19. Shioji K, Kishimoto C, Nakamura H, et al: Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002; 106: 1403-1409
20. Hoshino T, Nakamura H, Okamoto M, et al: Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 2003; 168:1075-1083
21. Ohashi S, Nishio A, Nakamura H, et al: Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G772-G781
22. Okubo K, Kosaka S, Isowa N, et al: Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung. J Thorac Cardiovasc Surg 1997; 113:1-9
23. Hattori I, Takagi Y, Nakamura H, et al: Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid Redox Signal 2004; 6:81-87
24. Liu W, Nakamura H, Shioji K, et al: Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 2004; 110:1276-1283
25. Nakamura H, Herzenberg LA, Bai J, et al: Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad SciUSA 2001; 98: 15143-15148
26. Tamaki H, Nakamura H, Nishio A, et al: Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006; 131:1110-1121
27. Bone RC, Sibbald WJ, Sprung CL: The ACCPSCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-1483
28. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
29. Breitkreutz R, Holm S, Pittack N, et al: Massive loss of sulfur in HIV infection. AIDS Res Hum Retroviruses 2000; 16:203-209
30. Bouchon A, Facchetti A, Weigand MA, et al: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410:1103-1107
31. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-170
32. Echtenacher B, Falk W, Mannel DN, et al: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-3766
33. Liliensiek B, Weigand MA, Bierhaus A, et al: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-1650
34. Powis G, Montfort WR: Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001; 41:261-295
35. Burke-Gaffney A, Callister ME, Nakamura H: Thioredoxin: Friend or foe in human disease? Trends Pharmacol Sci 2005; 26:398-404
36. Gromer S, Urig S, Becker K: The thioredoxin system - From science to clinic. Med Res Rev 2004; 24:40-89
37. Nakamura H: Thioredoxin as a key molecule in redox signaling. Antioxid Redox Signal 2004; 6:15-17
38. Kondo N, Ishii Y, Kwon YW, et al: Redoxsensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol 2004; 172:442-448
39. Sumida Y, Nakashima T, Yoh T, et al: Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33:616-622
40. Callister ME, Burke-Gaffney A, Quinlan GJ, et al: Persistently low plasma thioredoxin is associated with meningococcal septic shock in children. Intensive Care Med 2007; 33: 364-367
41. Hermans PW, Hibberd ML, Booy R, et al: 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354: 556-560
42. Kondo N, Ishii Y, Son A, et al: Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins. Immunol Lett 2004; 92:143-147
43. Nakamura H, De Rosa SC, Yodoi J, et al: Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad SciUSA 2001; 98:2688-2693
44. Angstwurm MW, Engelmann L, Zimmermann T, et al: Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35:118-126